Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Småbolagsdagen (June 2018)
19 slides from Cantargia Ab's conference presentation, Jun 11, 2018
Slide 1: We want to save patients with severe cancer and autoimmune diseases
We want to save patients with severe cancer and autoimmune diseases Entering clinical phase with our lead antibody CAN04 to our proprietary target Göran Forsberg, CEO 1
Slide 2: Safe Harbour Statement
Safe Harbour Statement The following presentation may include predictions, estimates or other information that might be considered forward-looking. The statements regarding the surrounding world and future circumstances in this presentation reflect Cantargia’s current thinking with respect to future
Slide 3: IL-1 blockade in cancer - Recent supportive clinical data
IL-1 blockade in cancer- Recent supportive clinical data CANTOS trial • Canakinumab (Novartis) Anakinra combination trials • Reduced lung cancer incidence Pancreatic cancer (metastatic) by 67 % and death by 77 %. Baylor college (14 pts) Combination with FOLFIRINOX Median survival 16.7 mo Placebo Col
Slide 4: CAN04 vs Canakinumab
CAN04 vs Canakinumab IL-1b Canakinumab IL-1a IL-33 • Antibody directed against one of the two IL-1 ligands, IL-1β CAN04: • Binds the common signaling IL1R1 IL1RAP ST2 receptor and counteracts both ligands • Induce killing via the immune system (ADCC) Cancer, Inflammation Asthma, Allergy (IL-6 & IL-8
Slide 5: Medical need and IL1RAP
Medical need and IL1RAP Normal cell Cancer cell • Cantargia founded based on: IL1RAP • Discovery of IL1RAP on cancer cells • Antibodies against IL1RAP had antitumor effects • NSCLC and pancreatic cancer are primary indications. 100 • Biomarker studies ongoing, to % patients with IL1RAP CML Colorecta
Slide 6: Cantargia at a glance
Cantargia at a glance Current owners (Mar 31, 2018) • Specialized in antibody therapy/immunology, with initial focus on Sunstone 9.0% oncology 1st AP fund 6.9% • Granted IP around therapeutic target and drug candidate • Lead antibody CAN04 in clinical development Avanza Pension 6.2% • Strong managem
Slide 7: Cantargia pipeline
Cantargia pipeline Project Discovery Preclinical Phase | phase phase Phase II Phase III Commercial phase CANO4 Non-small cell lung cancer Pancreatic cancer Leukemia CANxx Autoimmune and inflammatory diseases 7 @antargia
Slide 8: Cantargia business strategy
Cantargia business strategy Clinical study phase Partnership based on clinical data 8
Slide 9: Lead project CAN04 in the highest growth segment – Oncology antibodies
Lead project CAN04 in the highest growth segment– Oncology antibodies CAGR 6.9% CAGR 7.5-10.5% World’s most sold cancer drugs are antibodies 2017 (2016) Immuno-oncology driving market growth 2017 (2016) Rituxan/MabThera $7.87bn ($8.58bn) Opdivo $4.95bn ($3.77bn) Avastin $7.13bn ($6.75bn) Keytruda $3
Slide 10: CAN04 - immuno-oncology mechanism with antitumor effect
CAN04 - immuno-oncology mechanism with antitumor effect Cancer cells Inflammatory C A N 0 4 1 0 m g /k g ( n = 1 0 ) immune cells + N K 1 .1 in t u m o r 2500 20 V e h ic le p = 0 ,0 0 7 2 t u m o r tis s u e Stroma cells T u m o r v o lu m e ( m m ) 3 2000 Is o ty p e c o n tro l Blood vessels 15 C
Slide 11: Inflammation and metastasis
Inflammation and metastasis • Cancer cells (seeds) needs a good soil to form a metastasis • The IL-1 system (inflammation) can provide such environment (soil) A tumor can create its own ”seed and soil” 11
Slide 12: Tumor inflammation – key to cancer progression
Tumor inflammation – key to cancer progression Deregulating cellular Enablers energetics The inflammatory cytokine IL-1 – Well established role in Sustaining proliferative cancer progression: signaling Genomic instability and mutation (2000) Evading growth suppressors Tumor cells • Signaling/prolife
Slide 13: Non-small cell lung cancer (NSCLC)
Non-small cell lung cancer (NSCLC) Inflammation drives metaplasia and is a Smoking hallmark of active lung cancer Inflammation High mutational load Normal respiratory Mild hyperplasia Severe hyperplasia Squamous epithelium metaplasia Herfs et.al, Proinflammatory Cytokines Induce Bronchial Hyperplasi
Slide 14: CAN04 – CANFOUR clinical trial
CAN04 – CANFOUR clinical trial • Phase I/IIa trial - NSCLC and pancreatic cancer • Recruitment in Norway, Denmark Netherlands and Belgium • Well renowned centres (Jules Bordet, Brussels; Erasmus Rotterdam, NKI, Amsterdam; Rigshospitalet, Copenhagen; Radiumhospitalet, Oslo) • Dose group 1, safety eva
Slide 15: CANTOS additional findings (from Novartis IL-1β antibody)
CANTOS additional findings (from Novartis IL-1β antibody) CANCER decreased risk of death with treatment (high dose) Lung cancer 77 % P=0.0002 Non-lung cancer 37 % P=0.06 Decreased incidence of inflammatory disease (all doses) Arthritis 32% p<0.0001 Ostheoartritis 28% P=0.0005 Gout 53% p<0.0001 Bioma
Slide 16: IL1RAP - additional potential indications to leverage the value of our asset
IL1RAP - additional potential indications to leverage the value of our asset • Three different systems signal through IL1RAP • These systems contribute to various inflammatory diseases • Can be blocked by Cantargia’s antibodies against IL1RAP Cantargia partnership with Panorama Res Inc (Sunnyvale, C
Slide 17: Significant value inflection points ahead
Significant value inflection points ahead 2018 • Preclinical data on combination therapy • Preclinical studies to study immuno-oncology effects • Clinical plans and progress • Phase I clinical data (summer 2018) • Initiation of Phase IIa portion of the clinical trial (summer 2018) • US regulatory an
Slide 18: Cantargia IP
Cantargia IP Use of IL1RAP as target for hematological cancers Valid to 2030 Granted (EPO, USA, Japan, China) Use of IL1RAP as target for solid tumors Valid to 2032 Granted (EPO, Japan, USA, China) The product candidate CAN04 Valid to 2035 Granted EPO, USA New IL1RAP antibodies (e.g. CAN03) Filed 20
Slide 19: Cantargia summary
Cantargia summary • Focus on immuno-oncology - the strongest growing pharmaceutical segment • Taking advantage of established antibody technology to design novel pharmaceuticals • Lead candidate antibody CAN04 in clinical trial • Double mechanism of action • Initial development in NSCLC and pancreat